FDA approves drug that can delay onset of T1D

The FDA has now approved the use of teplizumab (Tzield), the world’s first ever immunotherapy for Type 1 diabetes, by people at risk of Type 1 diabetes.

A clinical trial found that teplizumab can delay Type 1 diabetes by an average of three years in people at high risk of developing the condition.

Chris Askew OBE, Chief Executive at Diabetes UK, said: “Today’s landmark approval of teplizumab in the US is the start of a seismic shift in how Type 1 diabetes is treated. For 100 years, people living with Type 1 diabetes have relied on insulin to treat the condition, and today’s decision means that for the first time, the root cause of the condition – an immune system attack – can be tackled, and Type 1 diabetes potentially delayed for up to three years.”

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).